Immunotherapy in GU Cancers Articles | Page 2

Pembrolizumab Update Solidifies Survival Benefit in Bladder Cancer
Joaquim Bellmunt, MD, PhD, discusses the updated pembrolizumab findings, as well as the future of immunotherapy in bladder cancer.
Powles Sheds Light on Shifting Landscape in Kidney Cancer
Thomas Powles MBBS, MRCP, MD, discusses the findings from the CheckMate-214 trial, as well as continuing studies in immunotherapy and targeted therapy in kidney cancer.
Pembrolizumab Survival Benefit Sustained in 2-Year Urothelial Cancer Data
Two-year follow-up data showed sustained improvements in overall survival with pembrolizumab over chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer.
Olaparib/Durvalumab Combo Shows Promise in mCRPC
The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.
Atezolizumab Combo Improves PFS by 3.5 Months in mRCC
The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.
New Model Predicts Survival Following Treatment With Atezolizumab for Bladder Cancer
A new model based on 6 clinical factors may be able to predict overall survival for patients with advanced urothelial cancers being treated with the PD-L1 inhibitor atezolizumab.
Balar Addresses Advances in Bladder and Kidney Cancer
Arjun V. Balar, MD, discusses the landscape of current and future standards of care for immunotherapy in bladder and kidney cancer.
Can Immunotherapy Bypass Sequential Care in RCC?
Despite positive clinical trial results, the role of immunotherapy in renal cell carcinoma remains unclear.
David R. Wise, MD, PhD, discusses the promise for immunotherapy and other emerging approaches in the field of prostate cancer.
Published Data Demonstrate Avelumab Activity in Platinum-Refractory Bladder Cancer
The PD-L1 inhibitor avelumab induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.
Publication Bottom Border
Border Publication